Innovation-driven trend shaping COVID-19 vaccine development in China

doi:10.1007/s11684-023-1034-6

Front. Med.

2023, Vol. 17

Issue (6) : 1096-1116 https://doi.org/10.1007/s11684-023-1034-6

Innovation-driven trend shaping COVID-19 vaccine development in China

Yuntao Zhang¹, Yuxiu Zhao¹, Hongyang Liang¹, Ying Xu¹, Chuge Zhou¹, Yuzhu Yao¹, Hui Wang¹(

), Xiaoming Yang^1,²(

)

¹. China National Biotec Group Company Limited, Beijing 100029, China
². National Engineering Technology Research Center of Combined Vaccines, Wuhan 430207, China

Download: PDF(1493 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Confronted with the coronavirus disease 2019 (COVID-19) pandemic, China has become an asset in tackling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and mutation, with several innovative platforms, which provides various technical means in this persisting combat. Derived from collaborated researches, vaccines based on the spike protein of SARS-CoV-2 or inactivated whole virus are a cornerstone of the public health response to COVID-19. Herein, we outline representative vaccines in multiple routes, while the merits and plights of the existing vaccine strategies are also summarized. Likewise, new technologies may provide more potent or broader immunity and will contribute to fight against hypermutated SARS-CoV-2 variants. All in all, with the ultimate aim of delivering robust and durable protection that is resilient to emerging infectious disease, alongside the traditional routes, the discovery of innovative approach to developing effective vaccines based on virus properties remains our top priority.

Keywords SARS-CoV-2 COVID-19 vaccine vaccine development

Corresponding Author(s): Hui Wang,Xiaoming Yang

Just Accepted Date: 14 November 2023 Online First Date: 18 December 2023 Issue Date: 06 February 2024

Cite this article:

Yuntao Zhang,Yuxiu Zhao,Hongyang Liang, et al. Innovation-driven trend shaping COVID-19 vaccine development in China[J]. Front. Med., 2023, 17(6): 1096-1116.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-023-1034-6
https://academic.hep.com.cn/fmd/EN/Y2023/V17/I6/1096

Fig.1 Schematic diagram of the SARS-CoV-2 virus particle and spike (S) protein. A schematic representation shows the SARS-CoV-2 and spike, the residue numbers of each region correspond to their positions in the S proteins of SARS-CoV-2.

Fig.2 An overview of the different platforms in vaccine development against COVID-19. A schematic representation shows the traditional vaccine platforms that are widely used in public health, and next-generation platforms, where very few have been licensed for use. COVID-19 vaccine tracker and landscape (who.int) are available to follow these representative vaccines through the clinical development and licensing process.

Tab.1 Representative COVID-19 vaccines approved or in clinical stage in China (as of March 2023)

Tab.2 Summary of major variants of concern (VOC) for SARS-CoV-2

Tab.3 Representative vaccine targeted VOCs in development

1	B Hu, H Guo, P Zhou, ZL Shi. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19(3): 141–154 https://doi.org/10.1038/s41579-020-00459-7
2	G Ritchie, DJ Harvey, F Feldmann, U Stroeher, H Feldmann, L Royle, RA Dwek, PM Rudd. Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein. Virology 2010; 399(2): 257–269 https://doi.org/10.1016/j.virol.2009.12.020
3	L Du, Y Yang, Y Zhou, L Lu, F Li, S Jiang. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets 2017; 21(2): 131–143 https://doi.org/10.1080/14728222.2017.1271415
4	SF Ahmed, AA Quadeer, MR McKay. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 2020; 12(3): 254 https://doi.org/10.3390/v12030254
5	Y Chen, Q Liu, D Guo. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020; 92(4): 418–423 https://doi.org/10.1002/jmv.25681
6	R Lu, X Zhao, J Li, P Niu, B Yang, H Wu, W Wang, H Song, B Huang, N Zhu, Y Bi, X Ma, F Zhan, L Wang, T Hu, H Zhou, Z Hu, W Zhou, L Zhao, J Chen, Y Meng, J Wang, Y Lin, J Yuan, Z Xie, J Ma, WJ Liu, D Wang, W Xu, EC Holmes, GF Gao, G Wu, W Chen, W Shi, W Tan. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565–574 https://doi.org/10.1016/S0140-6736(20)30251-8
7	MA Shereen, S Khan, A Kazmi, N Bashir, R Siddique. COVID-19 infection: emergence, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91–98 https://doi.org/10.1016/j.jare.2020.03.005
8	CB Jackson, M Farzan, B Chen, H Choe. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 2022; 23(1): 3–20 https://doi.org/10.1038/s41580-021-00418-x
9	P Zhou, XL Yang, XG Wang, B Hu, L Zhang, W Zhang, HR Si, Y Zhu, B Li, CL Huang, HD Chen, J Chen, Y Luo, H Guo, RD Jiang, MQ Liu, Y Chen, XR Shen, X Wang, XS Zheng, K Zhao, QJ Chen, F Deng, LL Liu, B Yan, FX Zhan, YY Wang, GF Xiao, ZL Shi. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270–273 https://doi.org/10.1038/s41586-020-2012-7
10	J Shang, Y Wan, C Luo, G Ye, Q Geng, A Auerbach, F Li. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA 2020; 117(21): 11727–11734 https://doi.org/10.1073/pnas.2003138117
11	KG Andersen, A Rambaut, WI Lipkin, EC Holmes, RF Garry. The proximal origin of SARS-CoV-2. Nat Med 2020; 26(4): 450–452 https://doi.org/10.1038/s41591-020-0820-9
12	D Wrapp, N Wang, KS Corbett, JA Goldsmith, CL Hsieh, O Abiona, BS Graham, JS McLellan. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367(6483): 1260–1263 https://doi.org/10.1126/science.abb2507
13	M Hoffmann, H Kleine-Weber, S Schroeder, N Krüger, T Herrler, S Erichsen, TS Schiergens, G Herrler, NH Wu, A Nitsche, MA Müller, C Drosten, S Pöhlmann. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271–280.e8 https://doi.org/10.1016/j.cell.2020.02.052
14	M Sadarangani, A Marchant, TR Kollmann. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 2021; 21(8): 475–484 https://doi.org/10.1038/s41577-021-00578-z
15	AU Anka, MI Tahir, SD Abubakar, M Alsabbagh, Z Zian, H Hamedifar, A Sabzevari, G Azizi. Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management. Scand J Immunol 2021; 93(4): e12998 https://doi.org/10.1111/sji.12998
16	P Mistry, F Barmania, J Mellet, K Peta, A Strydom, IM Viljoen, W James, S Gordon, MS Pepper. SARS-CoV-2 variants, vaccines, and host immunity. Front Immunol 2022; 12: 809244 https://doi.org/10.3389/fimmu.2021.809244
17	S Felsenstein, JA Herbert, PS McNamara, CM Hedrich. COVID-19: immunology and treatment options. Clin Immunol 2020; 215: 108448 https://doi.org/10.1016/j.clim.2020.108448
18	A Tarke, J Sidney, CK Kidd, JM Dan, SI Ramirez, ED Yu, J Mateus, R da Silva Antunes, E Moore, P Rubiro, N Methot, E Phillips, S Mallal, A Frazier, SA Rawlings, JA Greenbaum, B Peters, DM Smith, S Crotty, D Weiskopf, A Grifoni, A Sette. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med 2021; 2(2): 100204 https://doi.org/10.1016/j.xcrm.2021.100204
19	H Qi, B Liu, X Wang, L Zhang. The humoral response and antibodies against SARS-CoV-2 infection. Nat Immunol 2022; 23(7): 1008–1020 https://doi.org/10.1038/s41590-022-01248-5
20	L Lu, H Zhang, M Zhan, J Jiang, H Yin, DJ Dauphars, SY Li, Y Li, YW He. YW. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. Sci China Life Sci 2020; 63(12): 1833–1849 https://doi.org/10.1007/s11427-020-1859-y
21	MS Suthar, MG Zimmerman, RC Kauffman, G Mantus, SL Linderman, WH Hudson, A Vanderheiden, L Nyhoff, CW Davis, O Adekunle, M Affer, M Sherman, S Reynolds, HP Verkerke, DN Alter, J Guarner, J Bryksin, MC Horwath, CM Arthur, N Saakadze, GH Smith, S Edupuganti, EM Scherer, K Hellmeister, A Cheng, JA Morales, AS Neish, SR Stowell, F Frank, E Ortlund, EJ Anderson, VD Menachery, N Rouphael, AK Mehta, DS Stephens, R Ahmed, JD Roback, J Wrammert. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med 2020; 1(3): 100040 https://doi.org/10.1016/j.xcrm.2020.100040
22	A Reingold. Smallpox—the death of a disease: the inside story of eradicating a worldwide killer: By D. A. Henderson. Am J Epidemiol 2010; 171(3): 384–385 https://doi.org/10.1093/aje/kwp431
23	H Wang, Y Zhang, B Huang, W Deng, Y Quan, W Wang, W Xu, Y Zhao, N Li, J Zhang, H Liang, L Bao, Y Xu, L Ding, W Zhou, H Gao, J Liu, P Niu, L Zhao, W Zhen, H Fu, S Yu, Z Zhang, G Xu, C Li, Z Lou, M Xu, C Qin, G Wu, GF Gao, W Tan, X Yang. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 2020; 182(3): 713–721.e9 https://doi.org/10.1016/j.cell.2020.06.008
24	L Jin, Z Li, X Zhang, J Li, F Zhu. CoronaVac: a review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. Hum Vaccin Immunother 2022; 18(6): 2096970 https://doi.org/10.1080/21645515.2022.2096970
25	N Al Kaabi, Y Zhang, S Xia, Y Yang, MM Al Qahtani, N Abdulrazzaq, M Al Nusair, M Hassany, JS Jawad, J Abdalla, SE Hussein, SK Al Mazrouei, M Al Karam, X Li, X Yang, W Wang, B Lai, W Chen, S Huang, Q Wang, T Yang, Y Liu, R Ma, ZM Hussain, T Khan, M Saifuddin Fasihuddin, W You, Z Xie, Y Zhao, Z Jiang, G Zhao, Y Zhang, S Mahmoud, I ElTantawy, P Xiao, A Koshy, WA Zaher, H Wang, K Duan, A Pan, X Yang. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA 2021; 326(1): 35–45 https://doi.org/10.1001/jama.2021.8565
26	S Xia, K Duan, Y Zhang, D Zhao, H Zhang, Z Xie, X Li, C Peng, Y Zhang, W Zhang, Y Yang, W Chen, X Gao, W You, X Wang, Z Wang, Z Shi, Y Wang, X Yang, L Zhang, L Huang, Q Wang, J Lu, Y Yang, J Guo, W Zhou, X Wan, C Wu, W Wang, S Huang, J Du, Z Meng, A Pan, Z Yuan, S Shen, W Guo, X Yang. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 2020; 324(10): 951–960 https://doi.org/10.1001/jama.2020.15543
27	S Xia, Y Zhang, Y Wang, H Wang, Y Yang, GF Gao, W Tan, G Wu, M Xu, Z Lou, W Huang, W Xu, B Huang, H Wang, W Wang, W Zhang, N Li, Z Xie, L Ding, W You, Y Zhao, X Yang, Y Liu, Q Wang, L Huang, Y Yang, G Xu, B Luo, W Wang, P Liu, W Guo, X Yang. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021; 21(1): 39–51 https://doi.org/10.1016/S1473-3099(20)30831-8
28	L Bravo, I Smolenov, HH Han, P Li, R Hosain, F Rockhold, SAC Clemens, C Jr Roa, C Borja-Tabora, A Quinsaat, P Lopez, E López-Medina, L Brochado, EA Hernández, H Reynales, T Medina, H Velasquez, LB Toloza, EJ Rodriguez, Salazar DIM de, CA Rodríguez, E Sprinz, J Cerbino-Neto, KG Luz, AV Schwarzbold, MS Paiva, J Carlos, MEB Montellano, Los Reyes MRA de, CY Yu, ER Alberto, MM Panaligan, M Salvani-Bautista, E Buntinx, M Hites, JB Martinot, QE Bhorat, A Badat, C Baccarini, B Hu, J Jurgens, J Engelbrecht, D Ambrosino, P Richmond, G Siber, J Liang, R Clemens. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2022; 399(10323): 461–472 https://doi.org/10.1016/S0140-6736(22)00055-1
29	L Dai, L Gao, L Tao, SR Hadinegoro, M Erkin, Z Ying, P He, RT Girsang, H Vergara, J Akram, HI Satari, T Khaliq, U Sughra, AP Celi, F Li, Y Li, Z Jiang, D Dalimova, J Tuychiev, S Turdikulova, A Ikram, Lastra N Flores, F Ding, M Suhardono, E Fadlyana, J Yan, Z Hu, C Li, IY Abdurakhmonov, GF; ZF2001 Global Trial Group Gao. Efficacy and safety of the RBD-dimer-based Covid-19 vaccine ZF2001 in adults. N Engl J Med 2022; 386(22): 2097–2111 https://doi.org/10.1056/NEJMoa2202261
30	S Sun, Y Cai, TZ Song, Y Pu, L Cheng, H Xu, J Sun, C Meng, Y Lin, H Huang, F Zhao, S Zhang, Y Gao, JB Han, XL Feng, DD Yu, Y Zhu, P Gao, H Tang, J Zhao, Z Zhang, J Yang, Z Hu, YX Fu, YT Zheng, H Peng. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res 2021; 31(9): 1011–1023 https://doi.org/10.1038/s41422-021-00531-8
31	Jiangsu Recbio Technology Co. Ltd. Recbio announces new study showing its COVID-19 vaccine induced high levels of neutralizing antibodies against SARS-CoV-2 and variants of concern. PR Newswire. 2021
32	SA Halperin, L Ye, D MacKinnon-Cameron, B Smith, PE Cahn, GM Ruiz-Palacios, A Ikram, F Lanas, Guerrero M Lourdes, Navarro SR Muñoz, O Sued, DA Lioznov, V Dzutseva, G Parveen, F Zhu, L Leppan, JM Langley, L Barreto, J Gou, T; CanSino COVID-19 Global Efficacy Study Group Zhu. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet 2022; 399(10321): 237–248 https://doi.org/10.1016/S0140-6736(21)02753-7
33	F Zhu, C Zhuang, K Chu, L Zhang, H Zhao, S Huang, Y Su, H Lin, C Yang, H Jiang, X Zang, D Liu, H Pan, Y Hu, X Liu, Q Chen, Q Song, J Quan, Z Huang, G Zhong, J Chen, J Han, H Sun, L Cui, J Li, Y Chen, T Zhang, X Ye, C Li, T Wu, J Zhang, NS Xia. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med 2022; 10(8): 749–760 https://doi.org/10.1016/S2213-2600(22)00131-X
34	K Xu, W Lei, B Kang, H Yang, Y Wang, Y Lu, L Lv, Y Sun, J Zhang, X Wang, M Yang, M Dan, G Wu. A novel mRNA vaccine, SYS6006, against SARS-CoV-2. Front Immunol 2023; 13: 1051576 https://doi.org/10.3389/fimmu.2022.1051576
35	X Liu, Y Li, Z Wang, S Cao, W Huang, L Yuan, YJ Huang, Y Zheng, J Chen, B Ying, Z Xiang, J Shi, J Zhao, Z Huang, CF Qin. Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults. Cell Res 2022; 32(8): 777–780 https://doi.org/10.1038/s41422-022-00681-3
36	J Li, Q Liu, J Liu, Z Fang, L Luo, S Li, Y Lei, Z Li, J Jin, R Xie, Y Peng. Development of bivalent mRNA vaccines against SARS-CoV-2 variants. Vaccines (Basel) 2022; 10(11): 1807 https://doi.org/10.3390/vaccines10111807
37	P Tebas, S Yang, JD Boyer, EL Reuschel, A Patel, A Christensen-Quick, VM Andrade, MP Morrow, K Kraynyak, J Agnes, M Purwar, A Sylvester, J Pawlicki, E Gillespie, I Maricic, FI Zaidi, KY Kim, Y Dia, D Frase, P Pezzoli, K Schultheis, TRF Smith, SJ Ramos, T McMullan, K Buttigieg, MW Carroll, J Ervin, MC Diehl, E Blackwood, MP Mammen, J Lee, MJ Dallas, AS Brown, JE Shea, JJ Kim, DB Weiner, KE Broderick, LM Humeau. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine 2021; 31: 100689 https://doi.org/10.1016/j.eclinm.2020.100689
38	MR Hilleman, EB Buynak, RR Roehm, AA Tytell, AU Bertland, GP Lampson. Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci 1975; 270(2): 401–404 https://doi.org/10.1097/00000441-197509000-00025
39	H Okayasu, RW Sutter, HS Jafari, M Takane, RB Aylward. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis 2014; 210(Suppl 1): S459–S464 https://doi.org/10.1093/infdis/jiu128
40	QY Mao, Y Wang, L Bian, M Xu, Z Liang. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines 2016; 15(5): 599–606 https://doi.org/10.1586/14760584.2016.1138862
41	F Stauffer, T El-Bacha, AT Da Poian. Advances in the development of inactivated virus vaccines. Recent Patents Anti-Infect Drug Disc 2006; 1(3): 291–296 https://doi.org/10.2174/157489106778777673
42	C Rydyznski Moderbacher, SI Ramirez, JM Dan, A Grifoni, KM Hastie, D Weiskopf, S Belanger, RK Abbott, C Kim, J Choi, Y Kato, EG Crotty, C Kim, SA Rawlings, J Mateus, LPV Tse, A Frazier, R Baric, B Peters, J Greenbaum, E Ollmann Saphire, DM Smith, A Sette, S Crotty. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020; 183(4): 996–1012.e19 https://doi.org/10.1016/j.cell.2020.09.038
43	D Weiskopf, KS Schmitz, MP Raadsen, A Grifoni, NMA Okba, H Endeman, JPC van den Akker, R Molenkamp, MPG Koopmans, ECM van Gorp, BL Haagmans, RL de Swart, A Sette, RD de Vries. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol 2020; 5(48): eabd2071 https://doi.org/10.1126/sciimmunol.abd2071
44	K Duan, B Liu, C Li, H Zhang, T Yu, J Qu, M Zhou, L Chen, S Meng, Y Hu, C Peng, M Yuan, J Huang, Z Wang, J Yu, X Gao, D Wang, X Yu, L Li, J Zhang, X Wu, B Li, Y Xu, W Chen, Y Peng, Y Hu, L Lin, X Liu, S Huang, Z Zhou, L Zhang, Y Wang, Z Zhang, K Deng, Z Xia, Q Gong, W Zhang, X Zheng, Y Liu, H Yang, D Zhou, D Yu, J Hou, Z Shi, S Chen, Z Chen, X Zhang, X Yang. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; 117(17): 9490–9496 https://doi.org/10.1073/pnas.2004168117
45	E Cameroni, JE Bowen, LE Rosen, C Saliba, SK Zepeda, K Culap, D Pinto, LA VanBlargan, Marco A De, Iulio J di, F Zatta, H Kaiser, J Noack, N Farhat, N Czudnochowski, C Havenar-Daughton, KR Sprouse, JR Dillen, AE Powell, A Chen, C Maher, L Yin, D Sun, L Soriaga, J Bassi, C Silacci-Fregni, C Gustafsson, NM Franko, J Logue, NT Iqbal, I Mazzitelli, J Geffner, R Grifantini, H Chu, A Gori, A Riva, O Giannini, A Ceschi, P Ferrari, PE Cippà, A Franzetti-Pellanda, C Garzoni, PJ Halfmann, Y Kawaoka, C Hebner, LA Purcell, L Piccoli, MS Pizzuto, AC Walls, MS Diamond, A Telenti, HW Virgin, A Lanzavecchia, G Snell, D Veesler, D Corti. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 2022; 602(7898): 664–670 https://doi.org/10.1038/s41586-021-04386-2
46	S Shi, H Zhu, X Xia, Z Liang, X Ma, B Sun. Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity. Vaccine 2019; 37(24): 3167–3178 https://doi.org/10.1016/j.vaccine.2019.04.055
47	S Xia, Y Zhang, Y Wang, H Wang, Y Yang, GF Gao, W Tan, G Wu, M Xu, Z Lou, W Huang, W Xu, B Huang, H Wang, W Wang, W Zhang, N Li, Z Xie, L Ding, W You, Y Zhao, X Yang, Y Liu, Q Wang, L Huang, Y Yang, G Xu, B Luo, W Wang, P Liu, W Guo, X Yang. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021; 21(1): 39–51 https://doi.org/10.1016/S1473-3099(20)30831-8
48	B Han, Y Song, C Li, W Yang, Q Ma, Z Jiang, M Li, X Lian, W Jiao, L Wang, Q Shu, Z Wu, Y Zhao, Q Li, Q Gao. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21(12): 1645–1653 https://doi.org/10.1016/S1473-3099(21)00319-4
49	MD Tanriover, HL Doğanay, M Akova, HR Güner, A Azap, S Akhan, Ş Köse, FŞ Erdinç, EH Akalın, ÖF Tabak, H Pullukçu, Ö Batum, Yavuz S Şimşek, Ö Turhan, MT Yıldırmak, İ Köksal, Y Taşova, V Korten, G Yılmaz, MK Çelen, S Altın, İ Çelik, Y Bayındır, İ Karaoğlan, A Yılmaz, A Özkul, H Gür, S; CoronaVac Study Group Unal. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021; 398(10296): 213–222 https://doi.org/10.1016/S0140-6736(21)01429-X
50	R Ella, KM Vadrevu, H Jogdand, S Prasad, S Reddy, V Sarangi, B Ganneru, G Sapkal, P Yadav, P Abraham, S Panda, N Gupta, P Reddy, S Verma, S Kumar Rai, C Singh, SV Redkar, CS Gillurkar, JS Kushwaha, S Mohapatra, V Rao, R Guleria, K Ella, B Bhargava. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021; 21(5): 637–646 https://doi.org/10.1016/S1473-3099(20)30942-7
51	N Al Kaabi, A Oulhaj, S Ganesan, FI Al Hosani, O Najim, H Ibrahim, J Acuna, AR Alsuwaidi, AM Kamour, A Alzaabi, BA Al Shehhi, H Al Safar, SE Hussein, JS Abdalla, DSN Al Mansoori, AAK Al Hammadi, MA Amari, AK Al Romaithi, S Weber, S Elavalli, I Eltantawy, NK Alghaithi, JN Al Azazi, SG Holt, M Mostafa, R Halwani, H Khalak, W Elamin, R Beiram, W Zaher. Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates. Nat Commun 2022; 13(1): 3215 https://doi.org/10.1038/s41467-022-30835-1
52	SM Bueno, K Abarca, PA González, NMS Gálvez, JA Soto, LF Duarte, BM Schultz, GA Pacheco, LA González, Y Vázquez, M Ríos, F Melo-González, D Rivera-Pérez, C Iturriaga, M Urzúa, A Domínguez, CA Andrade, RV Berríos-Rojas, G Canedo-Marroquín, C Covián, D Moreno-Tapia, F Saavedra, OP Vallejos, P Donato, P Espinoza, D Fuentes, M González, P Guzmán, Venturelli P Muñoz, CM Pérez, M Potin, Á Rojas, RA Fasce, J Fernández, J Mora, E Ramírez, A Gaete-Argel, A Oyarzún-Arrau, F Valiente-Echeverría, R Soto-Rifo, D Weiskopf, A Sette, G Zeng, W Meng, JV González-Aramundiz, AM Kalergis. Safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in a subgroup of healthy adults in Chile. Clin Infect Dis 2022; 75(1): e792–e804 https://doi.org/10.1093/cid/ciab823
53	D Zhu, Y Hu, Z Jiang, T Yang, K Chu, H Zhang, J Hu, X Meng, Z Tan, J Wu, X Lian, C Li, H Pan. Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: a randomized, double-blind, phase IV trial. Hum Vaccin Immunother 2022; 18(6): 2135929 https://doi.org/10.1080/21645515.2022.2135929
54	Q Gao, L Bao, H Mao, L Wang, K Xu, M Yang, Y Li, L Zhu, N Wang, Z Lv, H Gao, X Ge, B Kan, Y Hu, J Liu, F Cai, D Jiang, Y Yin, C Qin, J Li, X Gong, X Lou, W Shi, D Wu, H Zhang, L Zhu, W Deng, Y Li, J Lu, C Li, X Wang, W Yin, Y Zhang, C Qin. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020; 369(6499): 77–81 https://doi.org/10.1126/science.abc1932
55	I Delrue, D Verzele, A Madder, HJ Nauwynck. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines 2012; 11(6): 695–719 https://doi.org/10.1586/erv.12.38
56	J Lan, J Ge, J Yu, S Shan, H Zhou, S Fan, Q Zhang, X Shi, Q Wang, L Zhang, X Wang. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581(7807): 215–220 https://doi.org/10.1038/s41586-020-2180-5
57	PT Heath, EP Galiza, DN Baxter, M Boffito, D Browne, F Burns, DR Chadwick, R Clark, C Cosgrove, J Galloway, AL Goodman, A Heer, A Higham, S Iyengar, A Jamal, C Jeanes, PA Kalra, C Kyriakidou, DF McAuley, A Meyrick, AM Minassian, J Minton, P Moore, I Munsoor, H Nicholls, O Osanlou, J Packham, CH Pretswell, Francisco Ramos A San, D Saralaya, RP Sheridan, R Smith, RL Soiza, PA Swift, EC Thomson, J Turner, ME Viljoen, G Albert, I Cho, F Dubovsky, G Glenn, J Rivers, A Robertson, K Smith, S; 2019nCoV-302 Study Group Toback. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 2021; 385(13): 1172–1183 https://doi.org/10.1056/NEJMoa2107659
58	L Dai, T Zheng, K Xu, Y Han, L Xu, E Huang, Y An, Y Cheng, S Li, M Liu, M Yang, Y Li, H Cheng, Y Yuan, W Zhang, C Ke, G Wong, J Qi, C Qin, J Yan, GF Gao. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 2020; 182(3): 722–733.e11 https://doi.org/10.1016/j.cell.2020.06.035
59	A Jafari, F Danesh Pouya, Z Niknam, M Abdollahpour-Alitappeh, M Rezaei-Tavirani, Y Rasmi. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms. Mol Biol Rep 2022; 49(6): 4943–4957 https://doi.org/10.1007/s11033-022-07132-7
60	L Dai, GF Gao. Viral targets for vaccines against COVID-19. Nat Rev Immunol 2021; 21(2): 73–82 https://doi.org/10.1038/s41577-020-00480-0
61	S Soleimanpour, A Yaghoubi. COVID-19 vaccine: where are we now and where should we go?. Expert Rev Vaccines 2021; 20(1): 23–44 https://doi.org/10.1080/14760584.2021.1875824
62	K Lundstrom. Viral vectors for COVID-19 vaccine development. Viruses 2021; 13(2): 317 https://doi.org/10.3390/v13020317
63	G Schiedner, N Morral, RJ Parks, Y Wu, SC Koopmans, C Langston, FL Graham, AL Beaudet, S Kochanek. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18(2): 180–183 https://doi.org/10.1038/ng0298-180
64	MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, DR Owens, M Voysey, PK Aley, B Angus, G Babbage, S Belij-Rammerstorfer, L Berry, S Bibi, M Bittaye, K Cathie, H Chappell, S Charlton, P Cicconi, EA Clutterbuck, R Colin-Jones, C Dold, KRW Emary, S Fedosyuk, M Fuskova, D Gbesemete, C Green, B Hallis, MM Hou, D Jenkin, CCD Joe, EJ Kelly, S Kerridge, AM Lawrie, A Lelliott, MN Lwin, R Makinson, NG Marchevsky, Y Mujadidi, APS Munro, M Pacurar, E Plested, J Rand, T Rawlinson, S Rhead, H Robinson, AJ Ritchie, AL Ross-Russell, S Saich, N Singh, CC Smith, MD Snape, R Song, R Tarrant, Y Themistocleous, KM Thomas, TL Villafana, SC Warren, MEE Watson, AD Douglas, AVS Hill, T Lambe, SC Gilbert, SN Faust, AJ; Oxford COVID Vaccine Trial Group Pollard. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021; 396(10267): 1979–1993 https://doi.org/10.1016/S0140-6736(20)32466-1
65	J Sadoff, G Gray, A Vandebosch, V Cárdenas, G Shukarev, B Grinsztejn, PA Goepfert, C Truyers, H Fennema, B Spiessens, K Offergeld, G Scheper, KL Taylor, ML Robb, J Treanor, DH Barouch, J Stoddard, MF Ryser, MA Marovich, KM Neuzil, L Corey, N Cauwenberghs, T Tanner, K Hardt, J Ruiz-Guiñazú, Gars M Le, H Schuitemaker, Hoof J Van, F Struyf, M; ENSEMBLE Study Group Douoguih. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021; 384(23): 2187–2201 https://doi.org/10.1056/NEJMoa2101544
66	C Jacob-Dolan, DH Barouch. COVID-19 vaccines: adenoviral vectors. Annu Rev Med 2022; 73(1): 41–54 https://doi.org/10.1146/annurev-med-012621-102252
67	F Chiuppesi, JA Zaia, PH Frankel, R Stan, J Drake, B Williams, AM Acosta, K Francis, RA Taplitz, JK Dickter, S Dadwal, AG Puing, DD Nanayakkara, P Ash, Y Cui, H Contreras, C La Rosa, K Tiemann, Y Park, J Medina, A Iniguez, Q Zhou, V Karpinski, D Johnson, K Faircloth, T Kaltcheva, J Nguyen, M Kha, VH Nguyen, SO Francisco, A Grifoni, A Wong, A Sette, F Wussow, DJ Diamond. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. Lancet Microbe 2022; 3(4): e252–e264 https://doi.org/10.1016/S2666-5247(22)00027-1
68	R Zhang, KH Chan, P Wang, R Zhou, HKC Yau, CKW Wong, MW Au, AR Tam, CT Ng, MK Lou, N Liu, H Huang, S Deng, RC Tam, Y Liu, T Long, HW Tsoi, MKW Ng, JP Cai, KK To, MF Yuen, Z Chen, H Chen, KY Yuen, IF Hung. A phase 1, randomized, double-blinded, placebo-controlled and dose-escalation study to evaluate the safety and immunogenicity of the intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in healthy adults. Vaccines (Basel) 2023; 11(4): 723 https://doi.org/10.3390/vaccines11040723
69	T Schlake, A Thess, M Fotin-Mleczek, KJ Kallen. Developing mRNA-vaccine technologies. RNA Biol 2012; 9(11): 1319–1330 https://doi.org/10.4161/rna.22269
70	LYY Lee, L Izzard, AC Hurt. A review of DNA vaccines against influenza. Front Immunol 2018; 9: 1568 https://doi.org/10.3389/fimmu.2018.01568
71	TRF Smith, A Patel, S Ramos, D Elwood, X Zhu, J Yan, EN Gary, SN Walker, K Schultheis, M Purwar, Z Xu, J Walters, P Bhojnagarwala, M Yang, N Chokkalingam, P Pezzoli, E Parzych, EL Reuschel, A Doan, N Tursi, M Vasquez, J Choi, E Tello-Ruiz, I Maricic, MA Bah, Y Wu, D Amante, DH Park, Y Dia, AR Ali, FI Zaidi, A Generotti, KY Kim, TA Herring, S Reeder, VM Andrade, K Buttigieg, G Zhao, JM Wu, D Li, L Bao, J Liu, W Deng, C Qin, AS Brown, M Khoshnejad, N Wang, J Chu, D Wrapp, JS McLellan, K Muthumani, B Wang, MW Carroll, JJ Kim, J Boyer, DW Kulp, LMPF Humeau, DB Weiner, KE Broderick. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 2020; 11(1): 2601 https://doi.org/10.1038/s41467-020-16505-0
72	VP Chavda, R Pandya, V Apostolopoulos. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Rev Vaccines 2021; 20(12): 1549–1560 https://doi.org/10.1080/14760584.2021.1987223
73	FP Polack, SJ Thomas, N Kitchin, J Absalon, A Gurtman, S Lockhart, JL Perez, Marc G Pérez, ED Moreira, C Zerbini, R Bailey, KA Swanson, S Roychoudhury, K Koury, P Li, WV Kalina, D Cooper, RW Jr Frenck, LL Hammitt, Ö Türeci, H Nell, A Schaefer, S Ünal, DB Tresnan, S Mather, PR Dormitzer, U Şahin, KU Jansen, WC; C4591001 Clinical Trial Group Gruber. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27): 2603–2615 https://doi.org/10.1056/NEJMoa2034577
74	D An, A Frassetto, E Jacquinet, M Eybye, J Milano, C DeAntonis, V Nguyen, R Laureano, J Milton, S Sabnis, CM Lukacs, LT Guey. Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia. EBioMedicine 2019; 45: 519–528 https://doi.org/10.1016/j.ebiom.2019.07.003
75	MM Silveira, GMSG Moreira, M Mendonça. DNA vaccines against COVID-19: perspectives and challenges. Life Sci 2021; 267: 118919 https://doi.org/10.1016/j.lfs.2020.118919
76	T Hanke. New vector and vaccine platforms: mRNA, DNA, viral vectors. Curr Opin HIV AIDS 2022; 17(6): 338–344 https://doi.org/10.1097/COH.0000000000000763
77	P Rojas-Pérez-Ezquerra, Quirós J Crespo, Molina P Tornero, Ochoa de Ocáriz ML Baeza, Ortuño JM Zubeldia. Safety of new mRNA vaccines against COVID-19 in severely allergic patients. J Investig Allergol Clin Immunol 2021; 31(2): 180–181 https://doi.org/10.18176/jiaci.0683
78	H Fathizadeh, S Afshar, MR Masoudi, P Gholizadeh, M Asgharzadeh, K Ganbarov, Ş Köse, M Yousefi, HS Kafil. SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: a review. Int J Biol Macromol 2021; 188: 740–750 https://doi.org/10.1016/j.ijbiomac.2021.08.076
79	P Tebas, S Yang, JD Boyer, EL Reuschel, A Patel, A Christensen-Quick, VM Andrade, MP Morrow, K Kraynyak, J Agnes, M Purwar, A Sylvester, J Pawlicki, E Gillespie, I Maricic, FI Zaidi, KY Kim, Y Dia, D Frase, P Pezzoli, K Schultheis, TRF Smith, SJ Ramos, T McMullan, K Buttigieg, MW Carroll, J Ervin, MC Diehl, E Blackwood, MP Mammen, J Lee, MJ Dallas, AS Brown, JE Shea, JJ Kim, DB Weiner, KE Broderick, LM Humeau. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial. EClinicalMedicine 2021; 31: 100689 https://doi.org/10.1016/j.eclinm.2020.100689
80	A Khobragade, S Bhate, V Ramaiah, S Deshpande, K Giri, H Phophle, P Supe, I Godara, R Revanna, R Nagarkar, J Sanmukhani, A Dey, TMC Rajanathan, K Kansagra, P; ZyCoV-D phase 3 Study Investigator Group Koradia. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet 2022; 399(10332): 1313–1321 https://doi.org/10.1016/S0140-6736(22)00151-9
81	T Momin, K Kansagra, H Patel, S Sharma, B Sharma, J Patel, R Mittal, J Sanmukhani, K Maithal, A Dey, H Chandra, CT Rajanathan, HP Pericherla, P Kumar, A Narkhede, D Parmar. Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine 2021; 38: 101020 https://doi.org/10.1016/j.eclinm.2021.101020
82	C Sheridan. First COVID-19 DNA vaccine approved, others in hot pursuit. Nat Biotechnol 2021; 39(12): 1479–1482 https://doi.org/10.1038/d41587-021-00023-5
83	L Li, N Petrovsky. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 2016; 15(3): 313–329 https://doi.org/10.1586/14760584.2016.1124762
84	M Shafaati, M Saidijam, M Soleimani, F Hazrati, R Mirzaei, B Amirheidari, H Tanzadehpanah, S Karampoor, S Kazemi, B Yavari, H Mahaki, M Safaei, F Rahbarizadeh, P Samadi, Y Ahmadyousefi. A brief review on DNA vaccines in the era of COVID-19. Future Virol 2022; 17(1): 49–66 https://doi.org/10.2217/fvl-2021-0170
85	MM Silveira, TL Oliveira, RA Schuch, AJA McBride, OA Dellagostin, DD Hartwig. DNA vaccines against leptospirosis: a literature review. Vaccine 2017; 35(42): 5559–5567 https://doi.org/10.1016/j.vaccine.2017.08.067
86	M Li, H Wang, L Tian, Z Pang, Q Yang, T Huang, J Fan, L Song, Y Tong, H Fan. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther 2022; 7(1): 146 https://doi.org/10.1038/s41392-022-00996-y
87	S Okamura, H Ebina. Could live attenuated vaccines better control COVID-19?. Vaccine 2021; 39(39): 5719–5726 https://doi.org/10.1016/j.vaccine.2021.08.018
88	PD Minor. Live attenuated vaccines: historical successes and current challenges. Virology 2015; 479-480: 379–392 https://doi.org/10.1016/j.virol.2015.03.032
89	Y Wang, C Yang, Y Song, JR Coleman, M Stawowczyk, J Tafrova, S Tasker, D Boltz, R Baker, L Garcia, O Seale, A Kushnir, E Wimmer, S Mueller. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc Natl Acad Sci USA 2021; 118(29): e2102775118 https://doi.org/10.1073/pnas.2102775118
90	R Wang, Q Zhang, J Ge, W Ren, R Zhang, J Lan, B Ju, B Su, F Yu, P Chen, H Liao, Y Feng, X Li, X Shi, Z Zhang, F Zhang, Q Ding, T Zhang, X Wang, L Zhang. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity 2021; 54(7): 1611–1621.e5 https://doi.org/10.1016/j.immuni.2021.06.003
91	X Li, W Wang, X Zhao, J Zai, Q Zhao, Y Li, A Chaillon. Transmission dynamics and evolutionary history of 2019-nCoV. J Med Virol 2020; 92(5): 501–511 https://doi.org/10.1002/jmv.25701
92	P Mlcochova, SA Kemp, MS Dhar, G Papa, B Meng, IATM Ferreira, R Datir, DA Collier, A Albecka, S Singh, R Pandey, J Brown, J Zhou, N Goonawardane, S Mishra, C Whittaker, T Mellan, R Marwal, M Datta, S Sengupta, K Ponnusamy, VS Radhakrishnan, A Abdullahi, O Charles, P Chattopadhyay, P Devi, D Caputo, T Peacock, C Wattal, N Goel, A Satwik, R Vaishya, M; Indian SARS-CoV-2 Genomics Consortium (INSACOG); Genotype to Phenotype Japan (G2P-Japan) Consortium; CITIID-NIHR BioResource COVID-19 Collaboration; Mavousian A Agarwal, JH Lee, J Bassi, C Silacci-Fegni, C Saliba, D Pinto, T Irie, I Yoshida, WL Hamilton, K Sato, S Bhatt, S Flaxman, LC James, D Corti, L Piccoli, WS Barclay, P Rakshit, A Agrawal, RK Gupta. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 2021; 599(7883): 114–119 https://doi.org/10.1038/s41586-021-03944-y
93	C Huai Luo, C Paul Morris, J Sachithanandham, A Amadi, DC Gaston, M Li, NJ Swanson, M Schwartz, EY Klein, A Pekosz, HH Mostafa. Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is associated with higher recovery of infectious virus compared to the Alpha variant in both unvaccinated and vaccinated individuals. Clin Infect Dis 2022; 75(1): e715–e725 https://doi.org/10.1093/cid/ciab986
94	WHO. SARS-CoV-2 Variants of Concern and Variants of Interest, updated 31 May 2021. 2021. Available at the website of WHO
95	WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. 2021. Available at the website of WHO
96	JRC Pulliam, C van Schalkwyk, N Govender, A von Gottberg, C Cohen, MJ Groome, J Dushoff, K Mlisana, H Moultrie. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science 2022; 376(6593): eabn4947 https://doi.org/10.1126/science.abn4947
97	J Chen, R Wang, NB Gilby, GW Wei. Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model 2022; 62(2): 412–422 https://doi.org/10.1021/acs.jcim.1c01451
98	FP LyngseCT KirkebyM DenwoodLE ChristiansenK MølbakCH Møller. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish households. medRxiv 2022; 2022.01.28.22270044 doi:10.1101/2022.01.28.22270044
99	JE Bowen, A Addetia, HV Dang, C Stewart, JT Brown, WK Sharkey, KR Sprouse, AC Walls, IG Mazzitelli, JK Logue, NM Franko, N Czudnochowski, AE Powell, E Jr Dellota, K Ahmed, AS Ansari, E Cameroni, A Gori, A Bandera, CM Posavad, JM Dan, Z Zhang, D Weiskopf, A Sette, S Crotty, NT Iqbal, D Corti, J Geffner, G Snell, R Grifantini, HY Chu, D Veesler. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science 2022; 377(6608): 890–894 https://doi.org/10.1126/science.abq0203
100	L Ciuffreda, JM Lorenzo-Salazar, de Artola D García-Martínez, H Gil-Campesino, J Alcoba-Florez, H Rodríguez-Pérez, A Íñigo-Campos, J Salas-Hernández, J Rodríguez-Nuñez, A Muñoz-Barrera, A Valenzuela-Fernández, O Díez-Gil, R González-Montelongo, C Flores. Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain). Emerg Microbes Infect 2023; 12(1): 2202281 https://doi.org/10.1080/22221751.2023.2202281
101	C Yue, W Song, L Wang, F Jian, X Chen, F Gao, Z Shen, Y Wang, X Wang, Y Cao. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis 2023; 23(3): 278–280 https://doi.org/10.1016/S1473-3099(23)00010-5
102	R Varghese, D Kumar, R Sharma. Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?. Hum Cell 2023; 36(3): 1218–1221 https://doi.org/10.1007/s13577-023-00903-9
103	E Domingo, C García-Crespo, R Lobo-Vega, C Perales. Mutation rates, mutation frequencies, and proofreading-repair activities in RNA virus genetics. Viruses 2021; 13(9): 1882 https://doi.org/10.3390/v13091882
104	J Chen, R Wang, M Wang, GW Wei. Mutations strengthened SARS-CoV-2 infectivity. J Mol Biol 2020; 432(19): 5212–5226 https://doi.org/10.1016/j.jmb.2020.07.009
105	M Lucas, U Karrer, A Lucas, P Klenerman. Viral escape mechanisms–escapology taught by viruses. Int J Exp Pathol 2001; 82(5): 269–286 https://doi.org/10.1046/j.1365-2613.2001.00204.x
106	A Muik, AK Wallisch, B Sänger, KA Swanson, J Mühl, W Chen, H Cai, D Maurus, R Sarkar, Ö Türeci, PR Dormitzer, U Şahin. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science 2021; 371(6534): 1152–1153 https://doi.org/10.1126/science.abg6105
107	S Jangra, C Ye, R Rathnasinghe, D; Personalized Virology Initiative study group; Krammer F Stadlbauer, V Simon, L Martinez-Sobrido, A García-Sastre, M Schotsaert. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe 2021; 2(7): e283–e284 https://doi.org/10.1016/S2666-5247(21)00068-9
108	CK Wibmer, F Ayres, T Hermanus, M Madzivhandila, P Kgagudi, B Oosthuysen, BE Lambson, T de Oliveira, M Vermeulen, K van der Berg, T Rossouw, M Boswell, V Ueckermann, S Meiring, A von Gottberg, C Cohen, L Morris, JN Bhiman, PL Moore. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med 2021; 27(4): 622–625 https://doi.org/10.1038/s41591-021-01285-x
109	N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, C Gower, M Kall, N Groves, AM O’Connell, D Simons, PB Blomquist, A Zaidi, S Nash, Binti Abdul Aziz N Iwani, S Thelwall, G Dabrera, R Myers, G Amirthalingam, S Gharbia, JC Barrett, R Elson, SN Ladhani, N Ferguson, M Zambon, CNJ Campbell, K Brown, S Hopkins, M Chand, M Ramsay, Bernal J Lopez. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 2022; 386(16): 1532–1546 https://doi.org/10.1056/NEJMoa2119451
110	KE Lyke, RL Atmar, CD Islas, CM Posavad, D Szydlo, Chourdhury R Paul, ME Deming, A Eaton, LA Jackson, AR Branche, Sahly HM El, CA Rostad, JM Martin, C Johnston, RE Rupp, MJ Mulligan, RC Brady, RW Jr Frenck, M Bäcker, AC Kottkamp, TM Babu, K Rajakumar, S Edupuganti, D Dobrzynski, RN Coler, JI Archer, S Crandon, JA Zemanek, ER Brown, KM Neuzil, DS Stephens, DJ Post, SU Nayak, MS Suthar, PC Roberts, JH Beigel, DC; DMID 21-0012 Study Group Montefiori. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med 2022; 3(7): 100679 https://doi.org/10.1016/j.xcrm.2022.100679
111	E Volz, S Mishra, M Chand, JC Barrett, R Johnson, L Geidelberg, WR Hinsley, DJ Laydon, G Dabrera, Á O'Toole, R Amato, M Ragonnet-Cronin, I Harrison, B Jackson, CV Ariani, O Boyd, NJ Loman, JT McCrone, S Gonçalves, D Jorgensen, R Myers, V Hill, DK Jackson, K Gaythorpe, N Groves, J Sillitoe, DP; COVID-19 Genomics UK (COG-UK) consortium; Flaxman S Kwiatkowski, O Ratmann, S Bhatt, S Hopkins, A Gandy, A Rambaut, NM Ferguson. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 2021; 593(7858): 266–269 https://doi.org/10.1038/s41586-021-03470-x
112	X Shen, H Tang, C McDanal, K Wagh, W Fischer, J Theiler, H Yoon, D Li, BF Haynes, KO Sanders, S Gnanakaran, N Hengartner, R Pajon, G Smith, GM Glenn, B Korber, DC Montefiori. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 2021; 29(4): 529–539.e3 https://doi.org/10.1016/j.chom.2021.03.002
113	H Tegally, E Wilkinson, M Giovanetti, A Iranzadeh, V Fonseca, J Giandhari, D Doolabh, S Pillay, EJ San, N Msomi, K Mlisana, Gottberg A von, S Walaza, M Allam, A Ismail, T Mohale, AJ Glass, S Engelbrecht, Zyl G Van, W Preiser, F Petruccione, A Sigal, D Hardie, G Marais, NY Hsiao, S Korsman, MA Davies, L Tyers, I Mudau, D York, C Maslo, D Goedhals, S Abrahams, O Laguda-Akingba, A Alisoltani-Dehkordi, A Godzik, CK Wibmer, BT Sewell, J Lourenço, LCJ Alcantara, Pond SL Kosakovsky, S Weaver, D Martin, RJ Lessells, JN Bhiman, C Williamson, Oliveira T de. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 2021; 592(7854): 438–443 https://doi.org/10.1038/s41586-021-03402-9
114	S Cele, I Gazy, L Jackson, SH Hwa, H Tegally, G Lustig, J Giandhari, S Pillay, E Wilkinson, Y Naidoo, F Karim, Y Ganga, K Khan, M Bernstein, AB Balazs, BI Gosnell, W Hanekom, MS; Network for Genomic Surveillance in South Africa; COMMIT-KZN Team; Lessells RJ Moosa, Oliveira T de, A Sigal. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 2021; 593(7857): 142–146 https://doi.org/10.1038/s41586-021-03471-w
115	NR Faria, TA Mellan, C Whittaker, IM Claro, DDS Candido, S Mishra, MAE Crispim, FCS Sales, I Hawryluk, JT McCrone, RJG Hulswit, LAM Franco, MS Ramundo, Jesus JG de, PS Andrade, TM Coletti, GM Ferreira, CAM Silva, ER Manuli, RHM Pereira, PS Peixoto, MUG Kraemer, N Jr Gaburo, CDC Camilo, H Hoeltgebaum, WM Souza, EC Rocha, Souza LM de, Pinho MC de, LJT Araujo, FSV Malta, Lima AB de, JDP Silva, DAG Zauli, ACS Ferreira, RP Schnekenberg, DJ Laydon, PGT Walker, HM Schlüter, Santos ALP Dos, MS Vidal, Caro VS Del, RMF Filho, Santos HM Dos, RS Aguiar, JL Proença-Modena, B Nelson, JA Hay, M Monod, X Miscouridou, H Coupland, R Sonabend, M Vollmer, A Gandy, CA Jr Prete, VH Nascimento, MA Suchard, TA Bowden, SLK Pond, CH Wu, O Ratmann, NM Ferguson, C Dye, NJ Loman, P Lemey, A Rambaut, NA Fraiji, MDPSS Carvalho, OG Pybus, S Flaxman, S Bhatt, EC Sabino. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 2021; 372(6544): 815–821 https://doi.org/10.1126/science.abh2644
116	W Dejnirattisai, D Zhou, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, HME Duyvesteyn, A Tuekprakhon, R Nutalai, B Wang, C López-Camacho, J Slon-Campos, TS Walter, D Skelly, Clemens SA Costa, FG Naveca, V Nascimento, F Nascimento, da Costa C Fernandes, PC Resende, A Pauvolid-Correa, MM Siqueira, C Dold, R Levin, T Dong, AJ Pollard, JC Knight, D Crook, T Lambe, E Clutterbuck, S Bibi, A Flaxman, M Bittaye, S Belij-Rammerstorfer, SC Gilbert, MW Carroll, P Klenerman, E Barnes, SJ Dunachie, NG Paterson, MA Williams, DR Hall, RJG Hulswit, TA Bowden, EE Fry, J Mongkolsapaya, J Ren, DI Stuart, GR Screaton. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 2021; 184(11): 2939–2954.e9 https://doi.org/10.1016/j.cell.2021.03.055
117	A Sheikh, J McMenamin, B Taylor, C; Public Health Scotland Robertson, EAVE II Collaborators the. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021; 397(10293): 2461–2462 https://doi.org/10.1016/S0140-6736(21)01358-1
118	J Lopez Bernal, N Andrews, C Gower, E Gallagher, R Simmons, S Thelwall, J Stowe, E Tessier, N Groves, G Dabrera, R Myers, CNJ Campbell, G Amirthalingam, M Edmunds, M Zambon, KE Brown, S Hopkins, M Chand, M Ramsay. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021; 385(7): 585–594 https://doi.org/10.1056/NEJMoa2108891
119	NN Nguyen, L Houhamdi, VT Hoang, D Stoupan, PE Fournier, D Raoult, P Colson, P Gautret. High rate of reinfection with the SARS-CoV-2 Omicron variant. J Infect 2022; 85(2): 174–211 https://doi.org/10.1016/j.jinf.2022.04.034
120	JA Lewnard, VX Hong, MM Patel, R Kahn, M Lipsitch, SY Tartof. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med 2022; 28(9): 1933–1943 https://doi.org/10.1038/s41591-022-01887-z
121	J Chen, GW Wei. Omicron BA.2 (B.1.1.529.2): high potential for becoming the next dominant variant. J Phys Chem Lett 2022; 13(17): 3840–3849 https://doi.org/10.1021/acs.jpclett.2c00469
122	B Zeng, L Gao, Q Zhou, K Yu, F Sun. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med 2022; 20(1): 200 https://doi.org/10.1186/s12916-022-02397-y
123	Y Liu, Z Wang, X Zhuang, S Zhang, Z Chen, Y Zou, J Sheng, T Li, W Tai, J Yu, Y Wang, Z Zhang, Y Chen, L Tong, X Yu, L Wu, D Chen, R Zhang, N Jin, W Shen, J Zhao, M Tian, X Wang, G Cheng. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nat Commun 2023; 14(1): 2179 https://doi.org/10.1038/s41467-023-37926-7
124	MH Shariare, MAK Parvez, GA Karikas, M Kazi. The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions. J Infect Public Health 2021; 14(2): 214–220 https://doi.org/10.1016/j.jiph.2020.12.009
125	SM Cheng, CKP Mok, KC Chan, SS Ng, BH Lam, LL Luk, FW Ko, C Chen, K Yiu, JK Li, KK Chan, LC Tsang, LL Poon, DS Hui, M Peiris. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022. Euro Surveill 2022; 27(18): 2200178 https://doi.org/10.2807/1560-7917.ES.2022.27.18.2200178
126	ME McMenamin, J Nealon, Y Lin, JY Wong, JK Cheung, EHY Lau, P Wu, GM Leung, BJ Cowling. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis 2022; 22(10): 1435–1443 https://doi.org/10.1016/S1473-3099(22)00345-0
127	CKP Mok, CA Cohen, SMS Cheng, C Chen, KO Kwok, K Yiu, TO Chan, M Bull, KC Ling, Z Dai, SS Ng, GC Lui, C Wu, GK Amarasinghe, DW Leung, SYS Wong, SA Valkenburg, M Peiris, DS Hui. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology 2022; 27(4): 301–310 https://doi.org/10.1111/resp.14191
128	DY Lin, Y Gu, Y Xu, B Wheeler, H Young, SK Sunny, Z Moore, D Zeng. Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. JAMA 2022; 328(14): 1415–1426 https://doi.org/10.1001/jama.2022.17876
129	OT Ng, K Marimuthu, N Lim, ZQ Lim, NM Thevasagayam, V Koh, CJ Chiew, S Ma, M Koh, PY Low, SB Tan, J Ho, S Maurer-Stroh, VJM Lee, YS Leo, KB Tan, AR Cook, CC Tan. Analysis of COVID-19 incidence and severity among adults vaccinated with 2-dose mRNA COVID-19 or inactivated SARS-CoV-2 vaccines with and without boosters in Singapore. JAMA Netw Open 2022; 5(8): e2228900 https://doi.org/10.1001/jamanetworkopen.2022.28900
130	WF Garcia-Beltran, KJ St Denis, A Hoelzemer, EC Lam, AD Nitido, ML Sheehan, C Berrios, O Ofoman, CC Chang, BM Hauser, J Feldman, AL Roederer, DJ Gregory, MC Poznansky, AG Schmidt, AJ Iafrate, V Naranbhai, AB Balazs. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 2022; 185(3): 457–466.e4 https://doi.org/10.1016/j.cell.2021.12.033
131	RL Atmar, KE Lyke, ME Deming, LA Jackson, AR Branche, Sahly HM El, CA Rostad, JM Martin, C Johnston, RE Rupp, MJ Mulligan, RC Brady, RW Jr Frenck, M Bäcker, AC Kottkamp, TM Babu, K Rajakumar, S Edupuganti, D Dobrzynski, RN Coler, CM Posavad, JI Archer, S Crandon, SU Nayak, D Szydlo, JA Zemanek, Islas CP Dominguez, ER Brown, MS Suthar, MJ McElrath, AB McDermott, SE O’Connell, DC Montefiori, A Eaton, KM Neuzil, DS Stephens, PC Roberts, JH; for the DMID 21-0012 Study Group Beigel. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med 2022; 386(11): 1046–1057 https://doi.org/10.1056/NEJMoa2116414
132	X Zhao, R Zhang, S Qiao, X Wang, W Zhang, W Ruan, L Dai, P Han, GF Gao. Omicron SARS-CoV-2 neutralization from inactivated and ZF2001 vaccines. N Engl J Med 2022; 387(3): 277–280 https://doi.org/10.1056/NEJMc2206900
133	KHD Crawford, AS Dingens, R Eguia, CR Wolf, N Wilcox, JK Logue, K Shuey, AM Casto, B Fiala, S Wrenn, D Pettie, NP King, AL Greninger, HY Chu, JD Bloom. Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis 2021; 223(2): 197–205 https://doi.org/10.1093/infdis/jiaa618
134	G Regev-Yochay, T Gonen, M Gilboa, M Mandelboim, V Indenbaum, S Amit, L Meltzer, K Asraf, C Cohen, R Fluss, A Biber, I Nemet, L Kliker, G Joseph, R Doolman, E Mendelson, LS Freedman, D Harats, Y Kreiss, Y Lustig. Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron. N Engl J Med 2022; 386(14): 1377–1380 https://doi.org/10.1056/NEJMc2202542
135	M Teles, CM Connolly, S Frey, TP Chiang, JL Alejo, BJ Boyarsky, AA Shah, J Albayda, L Christopher-Stine, WA Werbel, DL Segev, JJ Paik. Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series. Ann Rheum Dis 2022; 81(5): 738–740 https://doi.org/10.1136/annrheumdis-2021-221641
136	A Jara, EA Undurraga, JR Zubizarreta, C González, A Pizarro, J Acevedo, K Leo, F Paredes, T Bralic, V Vergara, M Mosso, F Leon, I Parot, P Leighton, P Suárez, JC Rios, H García-Escorza, R Araos. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health 2022; 10(6): e798–e806 https://doi.org/10.1016/S2214-109X(22)00112-7
137	Y Zhang, W Tan, Z Lou, B Huang, W Zhou, Y Zhao, J Zhang, H Liang, N Li, X Zhu, L Ding, Y Guo, Z He, Y He, Z Wang, B Ma, M Ma, S Zhao, Z Chang, X Zhao, X Zheng, G Wu, H Wang, X Yang. Immunogenicity evaluating of the multivalent COVID-19 inactivated vaccine against the SARS-CoV-2 variants. Vaccines (Basel) 2022; 10(6): 956 https://doi.org/10.3390/vaccines10060956
138	L Rutten, YT Lai, S Blokland, D Truan, IJM Bisschop, NM Strokappe, A Koornneef, D van Manen, GY Chuang, SK Farney, H Schuitemaker, PD Kwong, JPM Langedijk. A universal approach to optimize the folding and stability of prefusion-closed HIV-1 envelope trimers. Cell Rep 2018; 23(2): 584–595 https://doi.org/10.1016/j.celrep.2018.03.061
139	H Qiao, SL Pelletier, L Hoffman, J Hacker, RT Armstrong, JM White. Specific single or double proline substitutions in the “spring-loaded” coiled-coil region of the influenza hemagglutinin impair or abolish membrane fusion activity. J Cell Biol 1998; 141(6): 1335–1347 https://doi.org/10.1083/jcb.141.6.1335
140	A Krarup, D Truan, P Furmanova-Hollenstein, L Bogaert, P Bouchier, IJM Bisschop, MN Widjojoatmodjo, R Zahn, H Schuitemaker, JS McLellan, JPM Langedijk. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 2015; 6(1): 8143 https://doi.org/10.1038/ncomms9143
141	KM Hastie, MA Zandonatti, LM Kleinfelter, ML Heinrich, MM Rowland, K Chandran, LM Branco, JE Robinson, RF Garry, EO Saphire. Structural basis for antibody-mediated neutralization of Lassa virus. Science 2017; 356(6341): 923–928 https://doi.org/10.1126/science.aam7260
142	J Pallesen, N Wang, KS Corbett, D Wrapp, RN Kirchdoerfer, HL Turner, CA Cottrell, MM Becker, L Wang, W Shi, WP Kong, EL Andres, AN Kettenbach, MR Denison, JD Chappell, BS Graham, AB Ward, JS McLellan. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A 2017; 114(35): E7348–E7357 https://doi.org/10.1073/pnas.1707304114
143	CL Hsieh, JA Goldsmith, JM Schaub, AM DiVenere, HC Kuo, K Javanmardi, KC Le, D Wrapp, AG Lee, Y Liu, CW Chou, PO Byrne, CK Hjorth, NV Johnson, J Ludes-Meyers, AW Nguyen, J Park, N Wang, D Amengor, JJ Lavinder, GC Ippolito, JA Maynard, IJ Finkelstein, JS McLellan. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 2020; 369(6510): 1501–1505 https://doi.org/10.1126/science.abd0826
144	Y Cao, A Yisimayi, Y Bai, W Huang, X Li, Z Zhang, T Yuan, R An, J Wang, T Xiao, S Du, W Ma, L Song, Y Li, X Li, W Song, J Wu, S Liu, X Li, Y Zhang, B Su, X Guo, Y Wei, C Gao, N Zhang, Y Zhang, Y Dou, X Xu, R Shi, B Lu, R Jin, Y Ma, C Qin, Y Wang, Y Feng, J Xiao, XS Xie. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res 2021; 31(7): 732–741 https://doi.org/10.1038/s41422-021-00514-9
145	K Xu, P Gao, S Liu, S Lu, W Lei, T Zheng, X Liu, Y Xie, Z Zhao, S Guo, C Tang, Y Yang, W Yu, J Wang, Y Zhou, Q Huang, C Liu, Y An, R Zhang, Y Han, M Duan, S Wang, C Yang, C Wu, X Liu, G She, Y Liu, X Zhao, K Xu, J Qi, G Wu, X Peng, L Dai, P Wang, GF Gao. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 2022; 185(13): 2265–2278.e14 https://doi.org/10.1016/j.cell.2022.04.029
146	NA Kaabi, YK Yang, LF Du, K Xu, S Shao, Y Liang, Y Kang, JG Su, J Zhang, T Yang, S Hussein, MS ElDein, SS Yang, W Lei, XJ Gao, Z Jiang, X Cong, Y Tan, H Wang, M Li, HM Mekki, W Zaher, S Mahmoud, X Zhang, C Qu, DY Liu, J Zhang, M Yang, I Eltantawy, JW Hou, ZH Lei, P Xiao, ZN Wang, JL Yin, XY Mao, J Zhang, L Qu, YT Zhang, XM Yang, G Wu, QM Li. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nat Commun 2022; 13(1): 3654 https://doi.org/10.1038/s41467-022-31379-0
147	JG Liang, D Su, TZ Song, Y Zeng, W Huang, J Wu, R Xu, P Luo, X Yang, X Zhang, S Luo, Y Liang, X Li, J Huang, Q Wang, X Huang, Q Xu, M Luo, A Huang, D Luo, C Zhao, F Yang, JB Han, YT Zheng, P Liang. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun 2021; 12(1): 1346 https://doi.org/10.1038/s41467-021-21634-1
148	Y Zhao, W Ni, S Liang, L Dong, M Xiang, Z Cai, D Niu, Q Zhang, D Wang, Y Zheng, Z Zhang, D Zhou, W Guo, Y Pan, X Wu, Y Yang, Z Jing, Y Jiang, Y Chen, H Yan, Y Zhou, K Xu, K Lan. Vaccination with Span, an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice. Sci Transl Med 2023; 15(677): eabo3332 https://doi.org/10.1126/scitranslmed.abo3332
149	C He, J Yang, W Hong, Z Chen, D Peng, H Lei, A Alu, X He, Z Bi, X Jiang, G Jia, Y Yang, Y Zhou, W Yu, C Tang, Q Huang, M Yang, B Li, J Li, J Wang, H Que, L Chen, W Ren, D Wan, J Li, W Wang, G Shen, Z Zhao, L Yang, J Yang, Z Wang, Z Su, Y Wei, X Cen, Y Tanaka, X Song, S Lu, X Peng, G Lu, X Wei. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat Commun 2022; 13(1): 5459 https://doi.org/10.1038/s41467-022-33209-9
150	M Kanekiyo, CJ Wei, HM Yassine, PM McTamney, JC Boyington, JRR Whittle, SS Rao, WP Kong, L Wang, GJ Nabel. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013; 499(7456): 102–106 https://doi.org/10.1038/nature12202
151	J Jardine, JP Julien, S Menis, T Ota, O Kalyuzhniy, A McGuire, D Sok, PS Huang, S MacPherson, M Jones, T Nieusma, J Mathison, D Baker, AB Ward, DR Burton, L Stamatatos, D Nemazee, IA Wilson, WR Schief. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340(6133): 711–716 https://doi.org/10.1126/science.1234150
152	Y Yuan, X Zhang, R Chen, Y Li, B Wu, R Li, F Zou, X Ma, X Wang, Q Chen, J Deng, Y Zhang, T Chen, Y Lin, S Yan, X Zhang, C Li, X Bu, Y Peng, C Ke, K Deng, T Pan, X He, Y Zhang, H Zhang. A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2. Cell Rep 2022; 38(3): 110256 https://doi.org/10.1016/j.celrep.2021.110256
153	X Ma, F Zou, F Yu, R Li, Y Yuan, Y Zhang, X Zhang, J Deng, T Chen, Z Song, Y Qiao, Y Zhan, J Liu, J Zhang, X Zhang, Z Peng, Y Li, Y Lin, L Liang, G Wang, Y Chen, Q Chen, T Pan, X He, H Zhang. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 2020; 53(6): 1315–1330.e9 https://doi.org/10.1016/j.immuni.2020.11.015
154	H Sekimukai, N Iwata-Yoshikawa, S Fukushi, H Tani, M Kataoka, T Suzuki, H Hasegawa, K Niikura, K Arai, N Nagata. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. Microbiol Immunol 2020; 64(1): 33–51 https://doi.org/10.1111/1348-0421.12754
155	W Tai, B Chai, S Feng, X Zhuang, J Ma, M Pang, L Pan, Z Yang, M Tian, G Cheng. Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant. Signal Transduct Target Ther 2022; 7(1): 173 https://doi.org/10.1038/s41392-022-01041-8
156	W Sun, L He, H Zhang, X Tian, Z Bai, L Sun, L Yang, X Jia, Y Bi, T Luo, G Cheng, W Fan, W Liu, J Li. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. Signal Transduct Target Ther 2021; 6(1): 340 https://doi.org/10.1038/s41392-021-00750-w
157	Z Liu, W Xu, S Xia, C Gu, X Wang, Q Wang, J Zhou, Y Wu, X Cai, D Qu, T Ying, Y Xie, L Lu, Z Yuan, S Jiang. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther 2020; 5(1): 282 https://doi.org/10.1038/s41392-020-00402-5
158	JB Bale, S Gonen, Y Liu, W Sheffler, D Ellis, C Thomas, D Cascio, TO Yeates, T Gonen, NP King, D Baker. Accurate design of megadalton-scale two-component icosahedral protein complexes. Science 2016; 353(6297): 389–394 https://doi.org/10.1126/science.aaf8818
159	YF Kang, C Sun, J Sun, C Xie, Z Zhuang, HQ Xu, Z Liu, YH Liu, S Peng, RY Yuan, JC Zhao, MS Zeng. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. Nat Commun 2022; 13(1): 2674 https://doi.org/10.1038/s41467-022-30222-w
160	AC Walls, MC Miranda, A Schäfer, MN Pham, A Greaney, PS Arunachalam, MJ Navarro, MA Tortorici, K Rogers, MA O’Connor, L Shirreff, DE Ferrell, J Bowen, N Brunette, E Kepl, SK Zepeda, T Starr, CL Hsieh, B Fiala, S Wrenn, D Pettie, C Sydeman, KR Sprouse, M Johnson, A Blackstone, R Ravichandran, C Ogohara, L Carter, SW Tilles, R Rappuoli, SR Leist, DR Martinez, M Clark, R Tisch, DT O’Hagan, Der Most R Van, Voorhis WC Van, D Corti, JS McLellan, H Kleanthous, TP Sheahan, KD Smith, DH Fuller, F Villinger, J Bloom, B Pulendran, RS Baric, NP King, D Veesler. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 2021; 184(21): 5432–5447.e16 https://doi.org/10.1016/j.cell.2021.09.015
161	RT Eguia, KHD Crawford, T Stevens-Ayers, L Kelnhofer-Millevolte, AL Greninger, JA Englund, MJ Boeckh, JD Bloom. A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog 2021; 17(4): e1009453 https://doi.org/10.1371/journal.ppat.1009453
162	CL Hsieh, AP Werner, SR Leist, LJ Stevens, E Falconer, JA Goldsmith, CW Chou, OM Abiona, A West, K Westendorf, K Muthuraman, EJ Fritch, KH 3rd Dinnon, A Schäfer, MR Denison, JD Chappell, RS Baric, BS Graham, KS Corbett, JS McLellan. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Rep 2021; 37(5): 109929 https://doi.org/10.1016/j.celrep.2021.109929
163	NK Hurlburt, LJ Homad, I Sinha, MF Jennewein, AJ MacCamy, YH Wan, J Boonyaratanakornkit, AM Sholukh, AM Jackson, P Zhou, DR Burton, R Andrabi, G Ozorowski, AB Ward, L Stamatatos, M Pancera, AT McGuire. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. Commun Biol 2022; 5(1): 342 https://doi.org/10.1038/s42003-022-03262-7
164	K Bloom, F van den Berg, P Arbuthnot. Self-amplifying RNA vaccines for infectious diseases. Gene Ther 2021; 28(3–4): 117–129 https://doi.org/10.1038/s41434-020-00204-y
165	EC Lavelle, RW Ward. Mucosal vaccines—fortifying the frontiers. Nat Rev Immunol 2022; 22(4): 236–250 https://doi.org/10.1038/s41577-021-00583-2
166	K Dhama, M Dhawan, R Tiwari, TB Emran, S Mitra, AA Rabaan, S Alhumaid, ZA Alawi, A Al Mutair. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother 2022; 18(5): 2045853 https://doi.org/10.1080/21645515.2022.2045853
167	M Yu, Y Zhu, Y Li, Z Chen, Z Li, J Wang, Z Li, F Zhang, J Ding. Design of a recombinant multivalent epitope vaccine based on SARS-CoV-2 and its variants in immunoinformatics approaches. Front Immunol 2022; 13(May): 884433 https://doi.org/10.3389/fimmu.2022.884433
168	L Vangeel, W Chiu, Jonghe S De, P Maes, B Slechten, J Raymenants, E André, P Leyssen, J Neyts, D Jochmans. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res 2022; 198: 105252 https://doi.org/10.1016/j.antiviral.2022.105252
169	B Tang, F He, D Liu, F He, T Wu, M Fang, Z Niu, Z Wu, D Xu. AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2. Biomolecules 2022; 12(6): 746 https://doi.org/10.3390/biom12060746
170	YH Jin, L Cai, ZS Cheng, H Cheng, T Deng, YP Fan, C Fang, D Huang, LQ Huang, Q Huang, Y Han, B Hu, F Hu, BH Li, YR Li, K Liang, LK Lin, LS Luo, J Ma, LL Ma, ZY Peng, YB Pan, ZY Pan, XQ Ren, HM Sun, Y Wang, YY Wang, H Weng, CJ Wei, DF Wu, J Xia, Y Xiong, HB Xu, XM Yao, YF Yuan, TS Ye, XC Zhang, YW Zhang, YG Zhang, HM Zhang, Y Zhao, MJ Zhao, H Zi, XT Zeng, YY Wang, XH; for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management Wang, Team Research, Medicine Chapter of China International Exchange Evidence-Based, Association for Medical Promotive, Care (CPAM) Health. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7(1): 4 https://doi.org/10.1186/s40779-020-0233-6

[1]	Xiaoming Yang. Passive antibody therapy in emerging infectious diseases[J]. Front. Med., 2023, 17(6): 1117-1134.
[2]	Tiantian Li, Dongsheng Wang, Haiming Wei, Xiaoling Xu. Cytokine storm and translating IL-6 biology into effective treatments for COVID-19[J]. Front. Med., 2023, 17(6): 1080-1095.
[3]	Lu Liu, Chenxia Zhou, Huimin Jiang, Huimin Wei, Yifan Zhou, Chen Zhou, Xunming Ji. Epidemiology, pathogenesis, and management of coronavirus disease 2019-associated stroke[J]. Front. Med., 2023, 17(6): 1047-1067.
[4]	Dong Wei, Yusang Xie, Xuefei Liu, Rong Chen, Min Zhou, Xinxin Zhang, Jieming Qu. Pathogen evolution, prevention/control strategy and clinical features of COVID-19: experiences from China[J]. Front. Med., 2023, 17(6): 1030-1046.
[5]	Linhua Zhao, Chuanxi Tian, Yingying Yang, Huifang Guan, Yu Wei, Yuxin Zhang, Xiaomin Kang, Ling Zhou, Qingwei Li, Jing Ma, Li Wan, Yujiao Zheng, Xiaolin Tong. Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19[J]. Front. Med., 2023, 17(6): 1014-1029.
[6]	Gang Lu, Yun Ling, Minghao Jiang, Yun Tan, Dong Wei, Lu Jiang, Shuting Yu, Fangying Jiang, Shuai Wang, Yao Dai, Jinzeng Wang, Geng Wu, Xinxin Zhang, Guoyu Meng, Shengyue Wang, Feng Liu, Xiaohong Fan, Saijuan Chen. Primary assessment of the diversity of Omicron sublineages and the epidemiologic features of autumn/winter 2022 COVID-19 wave in Chinese mainland[J]. Front. Med., 2023, 17(4): 758-767.
[7]	Hao Wang, Yu Yuan, Bihao Wu, Mingzhong Xiao, Zhen Wang, Tingyue Diao, Rui Zeng, Li Chen, Yanshou Lei, Pinpin Long, Yi Guo, Xuefeng Lai, Yuying Wen, Wenhui Li, Hao Cai, Lulu Song, Wei Ni, Youyun Zhao, Kani Ouyang, Jingzhi Wang, Qi Wang, Li Liu, Chaolong Wang, An Pan, Xiaodong Li, Rui Gong, Tangchun Wu. Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents[J]. Front. Med., 2023, 17(4): 747-757.
[8]	Ziyu Fu, Dongguo Liang, Wei Zhang, Dongling Shi, Yuhua Ma, Dong Wei, Junxiang Xi, Sizhe Yang, Xiaoguang Xu, Di Tian, Zhaoqing Zhu, Mingquan Guo, Lu Jiang, Shuting Yu, Shuai Wang, Fangyin Jiang, Yun Ling, Shengyue Wang, Saijuan Chen, Feng Liu, Yun Tan, Xiaohong Fan. Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai[J]. Front. Med., 2023, 17(3): 562-575.
[9]	Xiaoguang Xu, Wei Zhang, Mingquan Guo, Chenlu Xiao, Ziyu Fu, Shuting Yu, Lu Jiang, Shengyue Wang, Yun Ling, Feng Liu, Yun Tan, Saijuan Chen. Integrated analysis of gut microbiome and host immune responses in COVID-19[J]. Front. Med., 2022, 16(2): 263-275.
[10]	Yi Zhang, Haocheng Zhang, Wenhong Zhang. SARS-CoV-2 variants, immune escape, and countermeasures[J]. Front. Med., 2022, 16(2): 196-207.
[11]	Yiming Shao, Yingqi Wu, Yi Feng, Wenxin Xu, Feng Xiong, Xinxin Zhang. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic[J]. Front. Med., 2022, 16(2): 185-195.
[12]	Wei Zhang, Xiaoguang Xu, Ziyu Fu, Jian Chen, Saijuan Chen, Yun Tan. PathogenTrack and Yeskit: tools for identifying intracellular pathogens from single-cell RNA-sequencing datasets as illustrated by application to COVID-19[J]. Front. Med., 2022, 16(2): 251-262.
[13]	Zehong Huang, Yingying Su, Tianying Zhang, Ningshao Xia. A review of the safety and efficacy of current COVID-19 vaccines[J]. Front. Med., 2022, 16(1): 39-55.
[14]	Yuntao Zhang, Yunkai Yang, Niu Qiao, Xuewei Wang, Ling Ding, Xiujuan Zhu, Yu Liang, Zibo Han, Feng Liu, Xinxin Zhang, Xiaoming Yang. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults[J]. Front. Med., 2022, 16(1): 93-101.
[15]	Li Ni, Zheng Wen, Xiaowen Hu, Wei Tang, Haisheng Wang, Ling Zhou, Lujin Wu, Hong Wang, Chang Xu, Xizhen Xu, Zhichao Xiao, Zongzhe Li, Chene Li, Yujian Liu, Jialin Duan, Chen Chen, Dan Li, Runhua Zhang, Jinliang Li, Yongxiang Yi, Wei Huang, Yanyan Chen, Jianping Zhao, Jianping Zuo, Jianping Weng, Hualiang Jiang, Dao Wen Wang. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial[J]. Front. Med., 2021, 15(5): 704-717.

Viewed

Full text

Abstract

Cited

Shared

Discussed